NASDAQ:SRDX - SurModics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$55.22 -1.85 (-3.24 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$55.22
Today's Range$54.28 - $56.80
52-Week Range$25.00 - $82.35
Volume66,403 shs
Average Volume78,611 shs
Market Capitalization$786.47 million
P/E Ratio112.69
Dividend YieldN/A
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. SurModics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:SRDX
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio2.32
Quick Ratio2.21


Trailing P/E Ratio112.69
Forward P/E Ratio690.25
P/E Growth73.38

Sales & Book Value

Annual Sales$81.34 million
Price / Sales9.10
Cash Flow$0.9276 per share
Price / Cash Flow59.53
Book Value$8.13 per share
Price / Book6.79


EPS (Most Recent Fiscal Year)$0.49
Net Income$-4,450,000.00
Net Margins-5.48%
Return on Equity6.12%
Return on Assets4.34%


Outstanding Shares13,400,000
Market Cap$786.47 million

SurModics (NASDAQ:SRDX) Frequently Asked Questions

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) announced its quarterly earnings results on Friday, November, 9th. The company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.06. The firm had revenue of $23.04 million for the quarter, compared to the consensus estimate of $22.54 million. SurModics had a positive return on equity of 6.12% and a negative net margin of 5.48%. View SurModics' Earnings History.

When is SurModics' next earnings date?

SurModics is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for SurModics.

What guidance has SurModics issued on next quarter's earnings?

SurModics issued an update on its FY 2019 earnings guidance on Friday, November, 9th. The company provided earnings per share (EPS) guidance of $-0.07-0.23 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.23. The company issued revenue guidance of $92-97 million, compared to the consensus revenue estimate of $90.37 million.

What price target have analysts set for SRDX?

4 analysts have issued twelve-month target prices for SurModics' shares. Their forecasts range from $74.00 to $90.00. On average, they expect SurModics' stock price to reach $80.3333 in the next year. This suggests a possible upside of 45.5% from the stock's current price. View Analyst Price Targets for SurModics.

What is the consensus analysts' recommendation for SurModics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SurModics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SurModics.

What are Wall Street analysts saying about SurModics stock?

Here are some recent quotes from research analysts about SurModics stock:
  • 1. According to Zacks Investment Research, "Surmodics outperformed its industry in a year's time. The company lately witnessed solid performance in its IVD segment, which gained from growth in antigen and stabilizer sales. The company also issued a solid guidance for fiscal 2018. Surmodics’ solid initiatives to strengthen research and development programs bode well. The company generated strong profits from the SurVeil agreement with Abbott Laboratories as well. On the flip side, Surmodics lately saw significantly high operating losses. Product sales declined due to shipment issues, particularly in the Medical Device segment. The company’s drug-coated balloons face stiff competition in niche space. The company’s margins are expected to stay under pressure, owing to expenses in the Irish facility infrastructure and lower Medical-Device product gross margins. The stock also looks overvalued at the moment." (11/16/2018)
  • 2. Needham & Company LLC analysts commented, "SRDX beat consensus F4Q18 revenue and EPS. Management provided FY19 revenue guidance that was above consensus while adjusted EPS guidance was below consensus. Revenue growth slowed to 14.9% in in F3Q18. SRDX’s 3Q18 gross margin was down 120 bps Y/Y and its non-GAAP operating margin was down 1,130 bps Y/Y. Given FY19 revenue guidance that we think is achievable and likely conservative and continued progress with SRDX’s DCB program, we reiterate our Buy rating." (11/9/2018)
  • 3. Barrington Research analysts commented, "We are now modeling adjusted FY/18 adjusted EPS of $(0.02) and revenue of $78.4 million. DCB: Patient enrollment for the company’s TRANSCEND pivotal clinical trial continues and about half of U.S.-based clinical sites have now been activated. As a reminder, the trial to treat peripheral artery disease in the upper leg will be randomized and is expected to include 446 patients at up to 60 clinical sites in the U.S. and 18 sites in Europe. It will feature a head-to-head comparison with a competitor’s already commercialized drug-coated balloon product 510(k) products: Surmodics has now received FDA approvals for its first three 510(k) products (two balloon catheters and a microcatheter). Management remains hopeful that it will enter into partnership for all three products over the next two to four quarters Recommendation: We are maintaining our OUTPERFORM investment rating on SRDX shares. Our new price target is $43, up from our previous $38." (5/3/2018)

Has SurModics been receiving favorable news coverage?

News headlines about SRDX stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SurModics earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.

Who are some of SurModics' key competitors?

Who are SurModics' key executives?

SurModics' management team includes the folowing people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 55)
  • Mr. Bryan K. Phillips, Sr. VP of Legal & HR, Gen. Counsel and Corp. Sec. (Age 47)
  • Mr. Charles W. Olson, Sr. VP of Commercial & Bus. Devel. - Medical Devices (Age 54)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 52)
  • Mr. Timothy J. Arens, VP of Corp. Devel. & Strategy, Interim VP of Fin. and CFO (Age 51)

Who are SurModics' major shareholders?

SurModics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.53%), Renaissance Technologies LLC (8.18%), Vanguard Group Inc. (6.06%), Vanguard Group Inc (6.03%), Trigran Investments Inc. (5.42%) and Dimensional Fund Advisors LP (4.82%). Company insiders that own SurModics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Gregg S Sutton, Jose H Bedoya, Joseph J Stich, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for SurModics.

Which major investors are selling SurModics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including Trigran Investments Inc., Teton Advisors Inc., Morgan Stanley, Royce & Associates LP, Rice Hall James & Associates LLC, Gabelli Funds LLC, Gamco Investors INC. ET AL and TIAA CREF Investment Management LLC. Company insiders that have sold SurModics company stock in the last year include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Gregg S Sutton, Jose H Bedoya, Joseph J Stich, Susan E Knight and Timothy J Arens. View Insider Buying and Selling for SurModics.

Which major investors are buying SurModics stock?

SRDX stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, AQR Capital Management LLC, Acadian Asset Management LLC, Castleark Management LLC, Renaissance Technologies LLC, American Century Companies Inc., Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for SurModics.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $55.22.

How big of a company is SurModics?

SurModics has a market capitalization of $786.47 million and generates $81.34 million in revenue each year. The company earns $-4,450,000.00 in net income (profit) each year or $0.49 on an earnings per share basis. SurModics employs 338 workers across the globe.

What is SurModics' official website?

The official website for SurModics is

How can I contact SurModics?

SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]

MarketBeat Community Rating for SurModics (NASDAQ SRDX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  447
MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by Staff

Featured Article: Systematic Risk

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel